Primary navigation

    Erwinaze

    Drug - Erwinaze (asparaginase Erwinia chryanthemi) [EUSA Pharma, Inc]

    June 2012

    Therapeutic area - Oncology

    Approval criteria

    • Patient has diagnosis of acute lymphoblastic leukemia (ALL) AND has developed a severe hypersensitivity reaction during treatment with E. coli-derived asparaginase

    E. coli-derived asparaginse products include Elspar (asparaginase) and Oncaspar (peg-asparagase).

    Background information

    NCCN guidelines recommend that patients who develop severe hypersensitivity reactions during treatment with E. coli asparaginase stop current therapy with the offending agent and switch to Erwinaze.  

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top